Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I
Non-small cell lung cancer (NSCLC) comprises of 84% of all lung cancer cases. The treatment options for NSCLC at advanced stages are chemotherapy and radiotherapy. Chemotherapy involves conventional nonspecific chemotherapeutics, and targeted-protein/receptor-specific small molecule inhibitors. Biol...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on drug delivery Jg. 18; H. 1; S. 73 - 102 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Taylor & Francis
02.01.2021
|
| Schlagworte: | |
| ISSN: | 1742-5247, 1744-7593, 1744-7593 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Non-small cell lung cancer (NSCLC) comprises of 84% of all lung cancer cases. The treatment options for NSCLC at advanced stages are chemotherapy and radiotherapy. Chemotherapy involves conventional nonspecific chemotherapeutics, and targeted-protein/receptor-specific small molecule inhibitors. Biologically targeted therapies such as an antibody-based immunotherapy have been approved in combination with conventional therapeutics. Approved targeted chemotherapy is directed against the kinase domains of mutated cellular receptors such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinases (ALK), neurotrophic receptor kinases (NTRK) and against downstream signaling molecules such as BRAF (v-raf murine sarcoma viral oncogene homolog B1). Approved biologically targeted therapy involves the use of anti-angiogenesis antibodies and antibodies against immune checkpoints.
The rationale for the employment of targeted therapeutics and the resistance that may develop to therapy are discussed. Novel targeted therapeutics in clinical trials are also included.
Molecular and histological profiling of a given tumor specimen to determine the aberrant onco-driver is a must before deciding a targeted therapeutic regimen for the patient. Periodic monitoring of the patients response to a given therapeutic regimen is also mandatory so that any semblance of resistance to therapy can be deciphered and the regimen may be accordingly altered. |
|---|---|
| AbstractList | Non-small cell lung cancer (NSCLC) comprises of 84% of all lung cancer cases. The treatment options for NSCLC at advanced stages are chemotherapy and radiotherapy. Chemotherapy involves conventional nonspecific chemotherapeutics, and targeted-protein/receptor-specific small molecule inhibitors. Biologically targeted therapies such as an antibody-based immunotherapy have been approved in combination with conventional therapeutics. Approved targeted chemotherapy is directed against the kinase domains of mutated cellular receptors such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinases (ALK), neurotrophic receptor kinases (NTRK) and against downstream signaling molecules such as BRAF (v-raf murine sarcoma viral oncogene homolog B1). Approved biologically targeted therapy involves the use of anti-angiogenesis antibodies and antibodies against immune checkpoints.
The rationale for the employment of targeted therapeutics and the resistance that may develop to therapy are discussed. Novel targeted therapeutics in clinical trials are also included.
Molecular and histological profiling of a given tumor specimen to determine the aberrant onco-driver is a must before deciding a targeted therapeutic regimen for the patient. Periodic monitoring of the patients response to a given therapeutic regimen is also mandatory so that any semblance of resistance to therapy can be deciphered and the regimen may be accordingly altered. Non-small cell lung cancer (NSCLC) comprises of 84% of all lung cancer cases. The treatment options for NSCLC at advanced stages are chemotherapy and radiotherapy. Chemotherapy involves conventional nonspecific chemotherapeutics, and targeted-protein/receptor-specific small molecule inhibitors. Biologically targeted therapies such as an antibody-based immunotherapy have been approved in combination with conventional therapeutics. Approved targeted chemotherapy is directed against the kinase domains of mutated cellular receptors such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinases (ALK), neurotrophic receptor kinases (NTRK) and against downstream signaling molecules such as BRAF (v-raf murine sarcoma viral oncogene homolog B1). Approved biologically targeted therapy involves the use of anti-angiogenesis antibodies and antibodies against immune checkpoints.INTRODUCTIONNon-small cell lung cancer (NSCLC) comprises of 84% of all lung cancer cases. The treatment options for NSCLC at advanced stages are chemotherapy and radiotherapy. Chemotherapy involves conventional nonspecific chemotherapeutics, and targeted-protein/receptor-specific small molecule inhibitors. Biologically targeted therapies such as an antibody-based immunotherapy have been approved in combination with conventional therapeutics. Approved targeted chemotherapy is directed against the kinase domains of mutated cellular receptors such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinases (ALK), neurotrophic receptor kinases (NTRK) and against downstream signaling molecules such as BRAF (v-raf murine sarcoma viral oncogene homolog B1). Approved biologically targeted therapy involves the use of anti-angiogenesis antibodies and antibodies against immune checkpoints.The rationale for the employment of targeted therapeutics and the resistance that may develop to therapy are discussed. Novel targeted therapeutics in clinical trials are also included.AREAS COVEREDThe rationale for the employment of targeted therapeutics and the resistance that may develop to therapy are discussed. Novel targeted therapeutics in clinical trials are also included.Molecular and histological profiling of a given tumor specimen to determine the aberrant onco-driver is a must before deciding a targeted therapeutic regimen for the patient. Periodic monitoring of the patients response to a given therapeutic regimen is also mandatory so that any semblance of resistance to therapy can be deciphered and the regimen may be accordingly altered.EXPERT OPINIONMolecular and histological profiling of a given tumor specimen to determine the aberrant onco-driver is a must before deciding a targeted therapeutic regimen for the patient. Periodic monitoring of the patients response to a given therapeutic regimen is also mandatory so that any semblance of resistance to therapy can be deciphered and the regimen may be accordingly altered. |
| Author | Misra, Ambikanandan Upadhya, Archana Yadav, Khushwant S. |
| Author_xml | – sequence: 1 givenname: Archana surname: Upadhya fullname: Upadhya, Archana organization: Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS – sequence: 2 givenname: Khushwant S. surname: Yadav fullname: Yadav, Khushwant S. organization: Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS – sequence: 3 givenname: Ambikanandan surname: Misra fullname: Misra, Ambikanandan email: Misraan@hotmail.com organization: Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32954834$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtv1DAUhS1URB_wE0BessnUzziBDWgEtFIlWJS15cfN1MixBzsRmn9P0pmyYAGb66ur71zrnnOJzlJOgNBrSjaUdOSaKsEkE2rDCKMb2jHJlXqGLpa5aJTs-dljz5oVOkeXtf4ghLeK0BfonLNeio6LC_Rwb8oOJvDYl3mHpwcoZn_AIeHlv6aOJkbsYClxTjvsTHJQ3uFtDCk4E3ENuxSG8DjHJnm8z7UGGwHXHOcp5FSbb6ZM-PYlej6YWOHV6b1C3z9_ut_eNHdfv9xuP941jrft1CjKpWyJ73vpLAciwHlvLYEOhDfCDgNtbWeMs4oLqSgFIYe-pWCJoz1n_Aq9Pe7dl_xzhjrpMdT1ApMgz1UzIURLWNfJBX1zQmc7gtf7EkZTDvrJnQWQR8CV5awCwx-EEr2moJ9S0GsK-pTConv_l86FyaxuTMWE-F_1h6M6pCGX0fzKJXo9mUPMZSiL06Fq_u8VvwFJW6Bo |
| CitedBy_id | crossref_primary_10_1016_j_bioorg_2025_108660 crossref_primary_10_1016_j_phrs_2022_106198 crossref_primary_10_3389_fimmu_2024_1369118 crossref_primary_10_1155_2021_4341517 crossref_primary_10_1016_j_molstruc_2025_143221 crossref_primary_10_3390_cancers16244144 crossref_primary_10_3389_fgene_2021_764270 crossref_primary_10_1186_s12935_023_02990_y crossref_primary_10_1002_cnr2_1970 crossref_primary_10_1016_j_microc_2024_110665 crossref_primary_10_1155_2022_3049619 crossref_primary_10_1016_j_heliyon_2025_e42052 crossref_primary_10_1155_2023_6407588 crossref_primary_10_3389_fonc_2023_1082539 crossref_primary_10_1016_j_bcp_2025_116928 crossref_primary_10_1038_s41388_024_03227_6 crossref_primary_10_3389_fonc_2025_1533059 crossref_primary_10_1039_D5RA04346H |
| Cites_doi | 10.1038/nature05945 10.1183/09059180.00004614 10.4103/sajc.sajc_111_19 10.1016/j.jtho.2016.11.398 10.1158/1078-0432.CCR-18-1541 10.1016/B978-0-12-799961-6.00002-0 10.1186/s12890-019-0964-x 10.1158/2159-8290.CD-16-0795 10.1158/1078-0432.CCR-19-0994 10.1177/1753465817750075 10.4137/CMO.S5074 10.1080/19420862.2016.1156829 10.1177/1753466618767611 10.1186/s12943-018-0796-y 10.1074/jbc.273.15.8971 10.1158/1535-7163.MCT-11-0415 10.1200/JCO.2019.37.15_suppl.TPS3162 10.1093/annonc/mdy177 10.1097/01.COT.0000513325.52233.f1 10.1172/JCI39104 10.1080/13543784.2019.1667332 10.1158/1078-0432.CCR-17-0478 10.18632/oncotarget.14109 10.1146/annurev-cancerbio-030419-033502 10.1016/j.jtho.2017.08.002 10.1038/s41392-019-0099-9 10.3390/ph3030572 10.1016/S0959-8049(16)33029-5 10.1158/2159-8290.CD-16-1237 10.1158/0008-5472.CAN-10-3879 10.1200/JCO.2009.22.1507 10.3390/ijms20040824 10.1038/nrc3239 10.1001/jama.2019.11058 10.1038/nrclinonc.2017.175 10.1038/nrclinonc.2017.166 10.1016/j.jtho.2019.05.041 10.1016/j.chembiol.2013.06.001 10.1007/s00280-018-3623-7 10.1155/2016/9214056 10.1038/s41598-019-45278-w 10.1371/journal.pone.0220101 10.1158/1078-0432.CCR-17-1192 10.1080/14737140.2019.1643239 10.1016/j.jtho.2018.08.304 10.1016/j.jtho.2017.04.010 10.1038/nature11404 10.1517/14796694.1.1.7 10.21037/tcr.2018.08.11 10.1056/NEJMoa1810865 10.1158/1078-0432.CCR-14-1213 10.1093/annonc/mdy336 10.1016/j.jtho.2016.11.1297 10.1007/978-3-319-53156-4_5 10.2165/00002512-200724050-00005 10.1200/JCO.2019.37.15_suppl.TPS3161 10.1172/jci.insight.124184 10.1007/s12094-019-02075-1 10.21037/jtd.2018.01.129 10.1016/S1470-2045(18)30649-1 10.1007/978-3-642-54490-3_12 10.1080/13543784.2018.1415324 10.1128/MCB.25.17.7734-7742.2005 10.3389/fonc.2018.00267 10.1016/S1470-2045(19)30504-2 10.1186/s13045-018-0654-9 10.1016/j.cllc.2012.09.007 10.1016/j.lungcan.2010.08.022 10.1002/cmdc.201800719 10.1158/1078-0432.CCR-18-0198 10.1158/0008-5472.CAN-19-2590 10.1517/14740338.5.3.469 10.1158/1078-0432.CCR-16-1887 10.1186/s13045-019-0779-5 10.1186/s12943-017-0600-4 10.3390/cancers11101480 10.1093/annonc/mdz282 10.1177/1758834016630976 10.4161/cbt.5.12.3546 10.4103/2278-330X.110506 10.1016/S0169-409X(02)00169-2 10.1016/B978-0-323-55433-6.00005-5 10.5732/cjc.012.10098 10.2147/TCRM.S147381 10.1158/2159-8290.CD-16-1123 10.1186/s13045-018-0645-x 10.1016/j.jtho.2019.10.003 10.1158/1535-7163.MCT-12-0620 10.1038/nature25183 10.1016/j.ctrv.2020.102022 10.1111/j.1349-7006.1994.tb02392.x 10.21037/jtd.2017.10.152 10.3747/co.25.3760 10.1681/ASN.V561288 10.1158/1535-7163.MCT-17-1206 10.1002/cncr.30869 10.1158/2159-8290.CD-18-0338 10.3390/cancers11091381 10.1002/(SICI)1097-0215(19970926)73:1<84::AID-IJC14>3.0.CO;2-5 10.1093/jnci/djr523 10.1016/j.jtho.2016.05.024 10.1016/j.cell.2017.06.009 10.1093/annonc/mdy542 10.1200/JCO.2016.67.2048 10.1016/j.cytogfr.2005.01.004 10.1093/annonc/mdv072 10.1186/1756-8722-6-27 10.1158/0008-5472.CAN-04-4235 10.1093/annonc/mdw559 10.1038/labinvest.2013.130 10.1016/j.jtho.2018.08.244 10.1080/13543784.2017.1316714 10.1038/nm0695-578 10.2174/156800907783220453 10.1186/s13045-019-0731-8 10.1158/2326-6066.CIR-14-0171 10.1056/NEJMoa1714448 10.1053/sonc.2001.27607 10.1038/nrc2088 10.1038/nrc.2016.2 10.1038/sj.bjc.6604344 10.1016/j.lungcan.2007.07.012 10.1016/j.jtho.2015.10.025 10.1093/annonc/mdz431 10.4103/0366-6999.194649 10.1155/2011/583929 10.1093/annonc/mdw305 10.1007/s40265-019-01142-9 10.2174/1568011023354290 10.1093/annonc/mdz383 10.1007/978-3-319-24223-1_10 10.1038/s41416-019-0573-8 10.1097/JTO.0b013e3181e981d9 10.1093/annonc/mdj919 10.1200/JCO.2006.06.1101 10.1634/theoncologist.2013-0095 10.1136/esmoopen-2017-000279 10.1158/1078-0432.CCR-09-1920 10.1093/annonc/mdq680 10.1016/j.jtho.2016.09.127 10.1634/theoncologist.2015-0084 10.1073/pnas.97.6.2515 10.1146/annurev.med.53.082901.103929 10.1158/1078-0432.CCR-08-3328 10.1016/j.trecan.2019.02.003 10.21037/tlcr.2017.08.02 10.1200/EDBK_240837 10.1016/S1470-2045(11)70129-2 10.1634/theoncologist.2018-0411 10.1200/JCO.2018.36.15_suppl.9062 10.1056/NEJMoa1801005 10.1038/s41571-018-0113-0 10.3816/CLC.2004.s.003 10.1093/jnci/92.16.1295 10.1016/S1470-2045(17)30679-4 10.1093/annonc/mdy275 10.1002/ijc.22977 10.3390/cancers11070923 10.1016/j.jtho.2018.08.610 10.1016/j.lungcan.2018.07.013 10.1016/j.lungcan.2019.09.011 10.1186/s12885-019-6107-1 10.1016/S1470-2045(18)30673-9 10.1080/15384047.2018.1480294 10.1016/B978-0-323-48565-4.00006-0 10.1002/cam4.238 10.2217/fon-2018-0594 10.4143/crt.2012.44.3.151 10.2217/fon.13.7 10.1016/j.critrevonc.2019.02.006 10.1097/JTO.0000000000000264 10.1158/2159-8290.CD-14-0765 10.1016/j.ctrv.2020.101974 10.1093/annonc/10.suppl_5.S83 10.1158/1078-0432.CCR-17-2398 10.1172/jci.insight.120858 10.1093/annonc/mdz043 10.1083/jcb.201804161 10.2147/OTT.S210365 10.1093/annonc/mdy292.118 10.1016/j.rcl.2013.08.006 10.1016/S1470-2045(19)30655-2 10.1093/annonc/mdz338.079 10.1200/JCO.2019.37.15_suppl.e20661 10.1016/j.clinthera.2005.09.010 10.3747/co.21.1740 10.18632/oncotarget.26545 10.1016/j.jtho.2019.08.1955 10.2217/lmt.14.12 10.1016/j.lungcan.2016.11.011 10.1146/annurev.immunol.26.021607.090331 10.1158/2159-8290.CD-16-0596 10.3390/cancers11081197 10.1016/j.mayocp.2019.01.013 10.1016/j.jtho.2018.08.597 10.1097/PPO.0000000000000303 10.1158/1078-0432.CCR-14-2748 10.1093/annonc/mdv591 10.4103/jcrt.JCRT_903_18 10.1016/j.jtho.2015.08.003 10.1093/jnci/91.19.1604 10.1158/1078-0432.CCR-18-1590 10.1002/ijc.28236 10.1038/s41586-019-1694-1 10.1634/theoncologist.2009-0317 10.1093/annonc/mdz244.006 10.21037/tlcr.2019.10.14 10.3747/co.25.3747 10.1007/s00280-015-2831-7 10.1016/j.jtho.2018.08.1427 10.1074/jbc.M115.709675 10.1158/1078-0432.CCR-11-3145 10.1200/JCO.19.02654 10.1177/147323001103900511 10.1136/esmoopen-2019-000548 10.1016/j.jtho.2019.02.017 10.1158/1078-0432.CCR-07-0793 10.1158/1078-0432.CCR-11-2109 10.18632/oncotarget.26424 10.1016/j.jtho.2018.08.901 10.1016/j.jtho.2018.08.243 10.1177/1753466619885530 10.1016/j.jtho.2016.11.1517 10.1038/s41392-019-0038-9 10.1039/C8DT00838H 10.1186/s13045-019-0818-2 10.1158/0008-5472.991.65.3 10.1136/esmoopen-2016-000060 10.1097/01.COT.0000531954.37266.62 10.1158/0008-5472.CAN-05-0031 10.1093/annonc/mdy288.035 10.1007/s40265-019-01164-3 10.1056/NEJMoa1716948 10.1158/1078-0432.CCR-17-0782 10.7150/jca.17093 10.1016/j.canlet.2017.08.031 10.1016/j.jtho.2019.08.1359 10.1016/j.jtho.2017.09.551 10.2147/DDDT.S194231 10.1158/1078-0432.CCR-11-2393 10.1016/j.annonc.2019.10.022 10.1242/jcs.030197 10.1016/S1470-2045(17)30680-0 10.1186/s12943-018-0906-x 10.2147/OTT.S189391 10.1016/0167-4781(95)00171-9 10.1083/jcb.201808077 10.1038/nature13385 10.1155/2013/972913 10.1016/S0025-6196(11)60735-0 10.1016/S1470-2045(19)30691-6 10.1177/1060028018824578 10.1016/j.jtho.2016.11.399 10.1177/1758834014567470 10.1016/j.jtho.2019.08.412 10.1007/978-3-319-91442-8_10 10.1016/j.cllc.2019.02.013 10.1038/362841a0 10.1177/1947601911423031 10.1007/s00432-004-0653-9 10.1093/oxfordjournals.annonc.a059324 10.1158/1078-0432.CCR-18-1341 10.1016/j.cllc.2019.05.003 10.1080/13543784.2017.1351543 10.1007/s40271-017-0229-9 10.21037/tlcr.2016.06.07 10.1016/j.phrs.2017.04.022 10.1183/09031936.00126714 10.1093/annonc/mdw321 10.1158/1078-0432.CCR-18-1959 10.2147/OTT.S171665 10.1007/s10147-012-0386-8 10.1038/s41698-017-0005-2 10.1016/j.lungcan.2017.06.004 10.4065/81.9.1241 10.1158/1541-7786.MCR-19-0419 10.1007/s12032-017-0967-5 10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-S 10.1111/j.1349-7006.2012.02327.x |
| ContentType | Journal Article |
| Copyright | 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 |
| Copyright_xml | – notice: 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1080/17425247.2021.1825377 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1744-7593 |
| EndPage | 102 |
| ExternalDocumentID | 32954834 10_1080_17425247_2021_1825377 1825377 |
| Genre | Review Journal Article |
| GroupedDBID | --- 00X 03L 0R~ 29G 4.4 53G 5GY AAMIU AAOUU ABEIZ ABJNI ABLIJ ABLKL ABXYU ACGFS ACIEZ ADCVX ADRBQ AECIN AENEX AEOZL AFRVT AGDLA AGMLL AIJEM AIRBT AIYSM AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU AQTUD BABNJ BLEHA CCCUG CS3 DKSSO DU5 EBS F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- P2P RNANH TASJS TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TZHSB V1S ~1N AAYXX CITATION 0BK AAPWH ABBAB ABJYH ABVAX ADTOD CAZVN DASJU DAWQK EJD M44 NPM 7X8 |
| ID | FETCH-LOGICAL-c366t-7135560d995cb3e04ecddbb0e8e4da4bff16b8aacb7345711e45f961eb0c19323 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 22 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000573657100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1742-5247 1744-7593 |
| IngestDate | Mon Jul 21 10:47:12 EDT 2025 Thu Jan 02 22:57:36 EST 2025 Tue Nov 18 21:29:57 EST 2025 Sat Nov 29 06:32:43 EST 2025 Mon Oct 20 23:48:39 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | targeted therapy therapeutics in clinics resistance Non-small cell lung cancer immunotherapy |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c366t-7135560d995cb3e04ecddbb0e8e4da4bff16b8aacb7345711e45f961eb0c19323 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 32954834 |
| PQID | 2444602885 |
| PQPubID | 23479 |
| PageCount | 30 |
| ParticipantIDs | crossref_primary_10_1080_17425247_2021_1825377 pubmed_primary_32954834 informaworld_taylorfrancis_310_1080_17425247_2021_1825377 proquest_miscellaneous_2444602885 crossref_citationtrail_10_1080_17425247_2021_1825377 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-02 |
| PublicationDateYYYYMMDD | 2021-01-02 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Expert opinion on drug delivery |
| PublicationTitleAlternate | Expert Opin Drug Deliv |
| PublicationYear | 2021 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | cit0077 cit0198 cit0078 cit0199 cit0075 cit0196 cit0076 cit0197 cit0073 cit0194 cit0195 cit0072 cit0193 cit0190 cit0070 cit0191 Fala L (cit0071) 2016; 9 Zarogoulidis K (cit0010) 2013; 5 cit0079 cit0066 cit0187 cit0067 cit0188 cit0185 cit0065 cit0186 cit0062 cit0183 cit0063 cit0184 cit0060 cit0061 cit0182 cit0180 Na SM (cit0112) 2010; 2 cit0068 cit0189 cit0069 cit0099 cit0097 cit0098 cit0095 cit0096 cit0093 cit0094 cit0091 cit0090 Scheper RJ (cit0092) 1993; 53 Barthelemy P (cit0040) 2014; 34 Lwin Z (cit0110) 2013; 5 cit0088 cit0089 cit0086 cit0087 cit0084 cit0085 cit0082 cit0083 cit0080 cit0081 Rossi G (cit0169) 2017; 8 cit0033 cit0154 cit0275 cit0034 cit0155 cit0276 cit0031 cit0152 cit0273 cit0032 cit0153 cit0274 cit0150 cit0271 cit0030 cit0272 cit0270 cit0039 cit0037 cit0158 cit0279 cit0038 cit0159 cit0035 cit0156 cit0277 cit0036 cit0157 cit0278 cit0022 cit0143 cit0264 cit0023 cit0144 cit0265 cit0020 cit0141 cit0262 cit0021 cit0263 cit0260 cit0140 cit0261 Rehman S (cit0223) 2018; 6 cit0028 cit0149 cit0029 Shih J (cit0231) 2017; 77 cit0026 cit0147 cit0268 cit0027 cit0148 cit0269 cit0024 cit0145 cit0266 cit0025 cit0146 cit0267 cit0055 Blair SL (cit0101) 1997; 57 cit0176 cit0297 cit0056 cit0177 cit0298 cit0053 cit0174 cit0295 cit0054 Neel DS (cit0142) 2017; 1 cit0296 cit0051 cit0172 cit0293 cit0052 cit0173 cit0294 cit0170 cit0291 cit0050 cit0171 cit0290 cit0059 cit0057 cit0178 cit0299 cit0058 cit0179 cit0044 cit0165 cit0286 cit0045 cit0166 cit0287 cit0042 cit0163 cit0284 cit0043 cit0164 cit0285 cit0161 cit0282 cit0041 cit0162 cit0283 cit0280 cit0160 cit0281 Lauro S (cit0064) 2014; 34 cit0049 cit0046 cit0167 cit0288 cit0047 cit0168 Bronte G (cit0192) 2019; 10 cit0289 cit0111 cit0232 cit0230 Cheong HT (cit0105) 2018; 15 cit0118 cit0239 cit0119 cit0237 cit0117 cit0238 cit0114 Stewart EL (cit0136) 2015; 4 cit0235 cit0115 cit0236 cit0233 cit0113 Estrada-Bernal A (cit0151) 2018; 17 cit0234 cit0220 cit0221 cit0109 cit0107 cit0228 cit0108 cit0229 cit0226 cit0106 cit0227 cit0103 cit0224 cit0104 cit0225 cit0222 cit0102 cit0011 cit0132 cit0253 cit0012 cit0133 cit0254 cit0130 cit0251 cit0131 cit0252 cit0250 Fu Y (cit0308) 2018; 1 Vtorushin SV (cit0100) 2014; 36 cit0019 cit0017 cit0138 cit0259 cit0018 cit0139 cit0015 cit0257 cit0016 cit0137 cit0258 cit0013 cit0134 cit0255 cit0014 cit0135 cit0256 cit0121 cit0242 cit0001 cit0122 cit0243 cit0240 cit0120 cit0241 Stuckler D (cit0123) 2005; 65 Dumontet C (cit0116) 2005; 92 Cobo M (cit0074) 2017; 8 Li X (cit0048) 2014; 7 cit0008 cit0129 cit0009 cit0006 cit0127 cit0248 cit0007 cit0128 cit0249 cit0004 cit0125 cit0005 cit0126 cit0247 cit0002 cit0244 cit0003 cit0124 cit0245 Subbiah V (cit0181) 2019; 3 cit0309 cit0307 cit0306 cit0305 cit0304 cit0303 cit0302 cit0301 cit0210 Uprety D (cit0300) 2019; 13 cit0219 cit0217 cit0218 cit0215 cit0213 cit0214 Ahn M (cit0292) 2019; 14 cit0211 cit0212 Margolis B (cit0175) 1994; 5 Nogova L (cit0246) 2017; 35 cit0208 cit0209 cit0206 cit0207 cit0204 cit0205 cit0202 cit0203 Ogoshi Y (cit0216) 2019; 17 cit0200 cit0201 |
| References_xml | – ident: cit0158 doi: 10.1038/nature05945 – ident: cit0137 doi: 10.1183/09059180.00004614 – ident: cit0073 doi: 10.4103/sajc.sajc_111_19 – ident: cit0035 doi: 10.1016/j.jtho.2016.11.398 – ident: cit0037 doi: 10.1158/1078-0432.CCR-18-1541 – ident: cit0089 doi: 10.1016/B978-0-12-799961-6.00002-0 – ident: cit0029 doi: 10.1186/s12890-019-0964-x – ident: cit0182 doi: 10.1158/2159-8290.CD-16-0795 – volume: 15 start-page: 901 issue: 1 year: 2018 ident: cit0105 publication-title: Oncol Lett – ident: cit0225 doi: 10.1158/1078-0432.CCR-19-0994 – ident: cit0279 doi: 10.1177/1753465817750075 – ident: cit0049 doi: 10.4137/CMO.S5074 – ident: cit0305 doi: 10.1080/19420862.2016.1156829 – ident: cit0174 doi: 10.1177/1753466618767611 – ident: cit0221 doi: 10.1186/s12943-018-0796-y – ident: cit0091 doi: 10.1074/jbc.273.15.8971 – ident: cit0273 doi: 10.1158/1535-7163.MCT-11-0415 – ident: cit0205 doi: 10.1200/JCO.2019.37.15_suppl.TPS3162 – ident: cit0301 doi: 10.1093/annonc/mdy177 – ident: cit0063 doi: 10.1097/01.COT.0000513325.52233.f1 – ident: cit0107 doi: 10.1172/JCI39104 – ident: cit0304 doi: 10.1080/13543784.2019.1667332 – ident: cit0253 doi: 10.1158/1078-0432.CCR-17-0478 – volume: 57 start-page: 152 issue: 1 year: 1997 ident: cit0101 publication-title: Cancer Res – ident: cit0244 doi: 10.18632/oncotarget.14109 – ident: cit0078 doi: 10.1146/annurev-cancerbio-030419-033502 – ident: cit0171 doi: 10.1016/j.jtho.2017.08.002 – ident: cit0140 doi: 10.1038/s41392-019-0099-9 – ident: cit0076 – ident: cit0297 doi: 10.3390/ph3030572 – ident: cit0190 doi: 10.1016/S0959-8049(16)33029-5 – ident: cit0193 doi: 10.1158/2159-8290.CD-16-1237 – ident: cit0165 doi: 10.1158/0008-5472.CAN-10-3879 – ident: cit0206 doi: 10.1200/JCO.2009.22.1507 – ident: cit0012 doi: 10.3390/ijms20040824 – ident: cit0278 doi: 10.1038/nrc3239 – ident: cit0014 doi: 10.1001/jama.2019.11058 – ident: cit0194 doi: 10.1038/nrclinonc.2017.175 – ident: cit0081 doi: 10.1038/nrclinonc.2017.166 – ident: cit0247 doi: 10.1016/j.jtho.2019.05.041 – ident: cit0189 doi: 10.1016/j.chembiol.2013.06.001 – ident: cit0235 doi: 10.1007/s00280-018-3623-7 – ident: cit0017 doi: 10.1155/2016/9214056 – ident: cit0033 doi: 10.1038/s41598-019-45278-w – volume: 7 start-page: 937 year: 2014 ident: cit0048 publication-title: Oncol Targets Ther – ident: cit0276 doi: 10.1371/journal.pone.0220101 – ident: cit0229 doi: 10.1158/1078-0432.CCR-17-1192 – ident: cit0028 doi: 10.1080/14737140.2019.1643239 – ident: cit0203 doi: 10.1016/j.jtho.2018.08.304 – ident: cit0277 doi: 10.1016/j.jtho.2017.04.010 – ident: cit0025 doi: 10.1038/nature11404 – ident: cit0120 doi: 10.1517/14796694.1.1.7 – ident: cit0168 doi: 10.21037/tcr.2018.08.11 – ident: cit0287 doi: 10.1056/NEJMoa1810865 – ident: cit0082 doi: 10.1158/1078-0432.CCR-14-1213 – ident: cit0153 doi: 10.1093/annonc/mdy336 – ident: cit0156 doi: 10.1016/j.jtho.2016.11.1297 – ident: cit0283 doi: 10.1007/978-3-319-53156-4_5 – ident: cit0045 doi: 10.2165/00002512-200724050-00005 – ident: cit0258 doi: 10.1200/JCO.2019.37.15_suppl.TPS3161 – ident: cit0039 doi: 10.1172/jci.insight.124184 – ident: cit0138 doi: 10.1007/s12094-019-02075-1 – ident: cit0020 doi: 10.21037/jtd.2018.01.129 – volume: 34 start-page: 1483 issue: 4 year: 2014 ident: cit0040 publication-title: Anticancer Res – ident: cit0059 doi: 10.1016/S1470-2045(18)30649-1 – ident: cit0197 doi: 10.1007/978-3-642-54490-3_12 – ident: cit0269 doi: 10.1080/13543784.2018.1415324 – ident: cit0133 doi: 10.1128/MCB.25.17.7734-7742.2005 – ident: cit0023 doi: 10.3389/fonc.2018.00267 – ident: cit0155 doi: 10.1016/S1470-2045(19)30504-2 – ident: cit0001 – ident: cit0119 doi: 10.1186/s13045-018-0654-9 – ident: cit0254 doi: 10.1016/j.cllc.2012.09.007 – ident: cit0079 doi: 10.1016/j.lungcan.2010.08.022 – ident: cit0250 doi: 10.1002/cmdc.201800719 – ident: cit0208 doi: 10.1158/1078-0432.CCR-18-0198 – ident: cit0270 doi: 10.1158/0008-5472.CAN-19-2590 – ident: cit0052 doi: 10.1517/14740338.5.3.469 – ident: cit0204 doi: 10.1158/1078-0432.CCR-16-1887 – ident: cit0281 doi: 10.1186/s13045-019-0779-5 – ident: cit0083 doi: 10.1186/s12943-017-0600-4 – ident: cit0178 doi: 10.3390/cancers11101480 – ident: cit0188 doi: 10.1093/annonc/mdz282 – ident: cit0245 doi: 10.1177/1758834016630976 – ident: cit0099 doi: 10.4161/cbt.5.12.3546 – ident: cit0018 doi: 10.4103/2278-330X.110506 – ident: cit0085 doi: 10.1016/S0169-409X(02)00169-2 – ident: cit0011 doi: 10.1016/B978-0-323-55433-6.00005-5 – ident: cit0255 doi: 10.5732/cjc.012.10098 – ident: cit0061 doi: 10.2147/TCRM.S147381 – ident: cit0162 doi: 10.1158/2159-8290.CD-16-1123 – ident: cit0114 doi: 10.1186/s13045-018-0645-x – ident: cit0234 doi: 10.1016/j.jtho.2019.10.003 – ident: cit0146 doi: 10.1158/1535-7163.MCT-12-0620 – volume: 3 start-page: 1 issue: 3 year: 2019 ident: cit0181 publication-title: JCO Precision Oncol – ident: cit0129 doi: 10.1038/nature25183 – ident: cit0227 doi: 10.1016/j.ctrv.2020.102022 – ident: cit0093 doi: 10.1111/j.1349-7006.1994.tb02392.x – ident: cit0068 doi: 10.21037/jtd.2017.10.152 – ident: cit0164 doi: 10.3747/co.25.3760 – volume: 5 start-page: 1288 issue: 6 year: 1994 ident: cit0175 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.V561288 – ident: cit0152 doi: 10.1158/1535-7163.MCT-17-1206 – ident: cit0209 doi: 10.1002/cncr.30869 – ident: cit0202 doi: 10.1158/2159-8290.CD-18-0338 – ident: cit0177 doi: 10.3390/cancers11091381 – ident: cit0007 – ident: cit0094 doi: 10.1002/(SICI)1097-0215(19970926)73:1<84::AID-IJC14>3.0.CO;2-5 – ident: cit0271 doi: 10.1093/jnci/djr523 – ident: cit0003 doi: 10.1016/j.jtho.2016.05.024 – ident: cit0176 doi: 10.1016/j.cell.2017.06.009 – ident: cit0215 doi: 10.1093/annonc/mdy542 – volume: 35 start-page: 157 issue: 2 year: 2017 ident: cit0246 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.67.2048 – ident: cit0298 doi: 10.1016/j.cytogfr.2005.01.004 – volume: 6 start-page: 100 issue: 1 year: 2018 ident: cit0223 publication-title: EMJ Respiratory – ident: cit0260 doi: 10.1093/annonc/mdv072 – ident: cit0268 doi: 10.1186/1756-8722-6-27 – ident: cit0147 doi: 10.1158/0008-5472.CAN-04-4235 – ident: cit0199 doi: 10.1093/annonc/mdw559 – ident: cit0282 doi: 10.1038/labinvest.2013.130 – ident: cit0220 doi: 10.1016/j.jtho.2018.08.244 – ident: cit0243 doi: 10.1080/13543784.2017.1316714 – ident: cit0090 doi: 10.1038/nm0695-578 – ident: cit0117 doi: 10.2174/156800907783220453 – volume: 92 start-page: E25 issue: 2 year: 2005 ident: cit0116 publication-title: Bull Cancer – ident: cit0166 doi: 10.1186/s13045-019-0731-8 – volume: 77 start-page: Abstract nr 209 issue: 13 year: 2017 ident: cit0231 publication-title: Cancer Res – volume: 13 start-page: 133 year: 2019 ident: cit0300 publication-title: Biologics. – ident: cit0307 doi: 10.1158/2326-6066.CIR-14-0171 – ident: cit0062 doi: 10.1056/NEJMoa1714448 – ident: cit0046 doi: 10.1053/sonc.2001.27607 – ident: cit0015 doi: 10.1038/nrc2088 – ident: cit0080 doi: 10.1038/nrc.2016.2 – ident: cit0121 doi: 10.1038/sj.bjc.6604344 – ident: cit0044 doi: 10.1016/j.lungcan.2007.07.012 – ident: cit0211 doi: 10.1016/j.jtho.2015.10.025 – ident: cit0201 doi: 10.1093/annonc/mdz431 – ident: cit0242 doi: 10.4103/0366-6999.194649 – ident: cit0103 doi: 10.1155/2011/583929 – ident: cit0163 doi: 10.1093/annonc/mdw305 – ident: cit0249 doi: 10.1007/s40265-019-01142-9 – ident: cit0115 doi: 10.2174/1568011023354290 – ident: cit0183 doi: 10.1093/annonc/mdz383 – ident: cit0111 doi: 10.1007/978-3-319-24223-1_10 – ident: cit0144 doi: 10.1038/s41416-019-0573-8 – ident: cit0051 doi: 10.1097/JTO.0b013e3181e981d9 – ident: cit0042 doi: 10.1093/annonc/mdj919 – ident: cit0122 doi: 10.1200/JCO.2006.06.1101 – ident: cit0170 doi: 10.1634/theoncologist.2013-0095 – ident: cit0217 doi: 10.1136/esmoopen-2017-000279 – ident: cit0263 doi: 10.1158/1078-0432.CCR-09-1920 – ident: cit0265 doi: 10.1093/annonc/mdq680 – ident: cit0226 doi: 10.1016/j.jtho.2016.09.127 – ident: cit0256 doi: 10.1634/theoncologist.2015-0084 – ident: cit0086 doi: 10.1073/pnas.97.6.2515 – ident: cit0075 doi: 10.1146/annurev.med.53.082901.103929 – ident: cit0212 doi: 10.1158/1078-0432.CCR-08-3328 – ident: cit0077 doi: 10.1016/j.trecan.2019.02.003 – ident: cit0196 doi: 10.21037/tlcr.2017.08.02 – ident: cit0284 doi: 10.1200/EDBK_240837 – volume: 5 start-page: S389 issue: 4 year: 2013 ident: cit0010 publication-title: J Thorac Dis – ident: cit0145 doi: 10.1016/S1470-2045(11)70129-2 – ident: cit0228 doi: 10.1634/theoncologist.2018-0411 – ident: cit0224 doi: 10.1200/JCO.2018.36.15_suppl.9062 – ident: cit0286 doi: 10.1056/NEJMoa1801005 – ident: cit0021 doi: 10.1038/s41571-018-0113-0 – ident: cit0126 doi: 10.3816/CLC.2004.s.003 – ident: cit0087 doi: 10.1093/jnci/92.16.1295 – ident: cit0060 doi: 10.1016/S1470-2045(17)30679-4 – ident: cit0008 doi: 10.1093/annonc/mdy275 – ident: cit0104 doi: 10.1002/ijc.22977 – ident: cit0134 doi: 10.3390/cancers11070923 – ident: cit0262 doi: 10.1016/j.jtho.2018.08.610 – ident: cit0022 doi: 10.1016/j.lungcan.2018.07.013 – ident: cit0198 doi: 10.1016/j.lungcan.2019.09.011 – ident: cit0050 doi: 10.1186/s12885-019-6107-1 – volume: 17 start-page: 2729 issue: 3 year: 2019 ident: cit0216 publication-title: Oncol Lett – ident: cit0289 doi: 10.1016/S1470-2045(18)30673-9 – ident: cit0241 doi: 10.1080/15384047.2018.1480294 – ident: cit0054 doi: 10.1016/B978-0-323-48565-4.00006-0 – ident: cit0239 doi: 10.1002/cam4.238 – ident: cit0070 doi: 10.2217/fon-2018-0594 – ident: cit0108 doi: 10.4143/crt.2012.44.3.151 – ident: cit0041 doi: 10.2217/fon.13.7 – ident: cit0157 doi: 10.1016/j.critrevonc.2019.02.006 – ident: cit0132 doi: 10.1097/JTO.0000000000000264 – ident: cit0185 doi: 10.1158/2159-8290.CD-14-0765 – ident: cit0259 doi: 10.1016/j.ctrv.2020.101974 – ident: cit0084 doi: 10.1093/annonc/10.suppl_5.S83 – ident: cit0031 doi: 10.1158/1078-0432.CCR-17-2398 – ident: cit0141 doi: 10.1172/jci.insight.120858 – ident: cit0210 doi: 10.1093/annonc/mdz043 – ident: cit0102 doi: 10.1083/jcb.201804161 – volume: 8 start-page: 45 year: 2017 ident: cit0169 publication-title: Lung Cancer – ident: cit0232 doi: 10.2147/OTT.S210365 – ident: cit0236 doi: 10.1093/annonc/mdy292.118 – ident: cit0004 doi: 10.1016/j.rcl.2013.08.006 – ident: cit0172 doi: 10.1016/S1470-2045(19)30655-2 – ident: cit0233 doi: 10.1093/annonc/mdz338.079 – ident: cit0251 doi: 10.1200/JCO.2019.37.15_suppl.e20661 – ident: cit0127 doi: 10.1016/j.clinthera.2005.09.010 – volume: 10 start-page: 27 year: 2019 ident: cit0192 publication-title: Lung Cancer – ident: cit0057 doi: 10.3747/co.21.1740 – ident: cit0264 doi: 10.18632/oncotarget.26545 – ident: cit0291 doi: 10.1016/j.jtho.2019.08.1955 – ident: cit0106 doi: 10.2217/lmt.14.12 – ident: cit0222 doi: 10.1016/j.lungcan.2016.11.011 – ident: cit0280 doi: 10.1146/annurev.immunol.26.021607.090331 – ident: cit0161 doi: 10.1158/2159-8290.CD-16-0596 – ident: cit0179 doi: 10.3390/cancers11081197 – ident: cit0009 doi: 10.1016/j.mayocp.2019.01.013 – volume: 8 start-page: 57 year: 2017 ident: cit0074 publication-title: Lung Cancer – ident: cit0219 doi: 10.1016/j.jtho.2018.08.597 – ident: cit0285 doi: 10.1097/PPO.0000000000000303 – ident: cit0130 doi: 10.1158/1078-0432.CCR-14-2748 – ident: cit0252 doi: 10.1093/annonc/mdv591 – ident: cit0069 doi: 10.4103/jcrt.JCRT_903_18 – ident: cit0240 doi: 10.1016/j.jtho.2015.08.003 – ident: cit0088 doi: 10.1093/jnci/91.19.1604 – ident: cit0218 doi: 10.1158/1078-0432.CCR-18-1590 – ident: cit0272 doi: 10.1002/ijc.28236 – ident: cit0034 doi: 10.1038/s41586-019-1694-1 – ident: cit0299 doi: 10.1634/theoncologist.2009-0317 – ident: cit0032 doi: 10.1093/annonc/mdz244.006 – ident: cit0128 doi: 10.21037/tlcr.2019.10.14 – ident: cit0293 doi: 10.3747/co.25.3747 – ident: cit0124 doi: 10.1007/s00280-015-2831-7 – ident: cit0149 doi: 10.1016/j.jtho.2018.08.1427 – ident: cit0191 doi: 10.1074/jbc.M115.709675 – ident: cit0275 doi: 10.1158/1078-0432.CCR-11-3145 – ident: cit0180 doi: 10.1200/JCO.19.02654 – ident: cit0097 doi: 10.1177/147323001103900511 – ident: cit0238 – ident: cit0019 doi: 10.1136/esmoopen-2019-000548 – ident: cit0213 doi: 10.1016/j.jtho.2019.02.017 – ident: cit0303 doi: 10.1158/1078-0432.CCR-07-0793 – ident: cit0024 doi: 10.1158/1078-0432.CCR-11-2109 – ident: cit0038 doi: 10.18632/oncotarget.26424 – ident: cit0150 doi: 10.1016/j.jtho.2018.08.901 – volume: 2 start-page: 1 issue: 1 year: 2010 ident: cit0112 publication-title: J Clin Med Res – ident: cit0148 doi: 10.1016/j.jtho.2018.08.243 – ident: cit0065 doi: 10.1177/1753466619885530 – ident: cit0131 – ident: cit0309 doi: 10.1016/j.jtho.2016.11.1517 – ident: cit0154 doi: 10.1038/s41392-019-0038-9 – ident: cit0043 doi: 10.1039/C8DT00838H – ident: cit0139 doi: 10.1186/s13045-019-0818-2 – volume: 65 start-page: 991 issue: 3 year: 2005 ident: cit0123 publication-title: Cancer Res doi: 10.1158/0008-5472.991.65.3 – volume: 53 start-page: 1475 issue: 7 year: 1993 ident: cit0092 publication-title: Cancer Res – ident: cit0135 doi: 10.1136/esmoopen-2016-000060 – volume: 34 start-page: 1537 issue: 4 year: 2014 ident: cit0064 publication-title: Anticancer Res – ident: cit0067 doi: 10.1097/01.COT.0000531954.37266.62 – ident: cit0302 doi: 10.1158/0008-5472.CAN-05-0031 – volume: 9 start-page: 119 year: 2016 ident: cit0071 publication-title: Am Health Drug Benefits – ident: cit0290 doi: 10.1093/annonc/mdy288.035 – ident: cit0013 doi: 10.1007/s40265-019-01164-3 – ident: cit0288 doi: 10.1056/NEJMoa1716948 – ident: cit0237 doi: 10.1158/1078-0432.CCR-17-0782 – volume: 36 start-page: 144 issue: 3 year: 2014 ident: cit0100 publication-title: Exp Oncol – ident: cit0207 doi: 10.7150/jca.17093 – ident: cit0266 doi: 10.1016/j.canlet.2017.08.031 – ident: cit0027 doi: 10.1016/j.jtho.2019.08.1359 – ident: cit0274 doi: 10.1016/j.jtho.2017.09.551 – ident: cit0214 doi: 10.2147/DDDT.S194231 – ident: cit0066 – ident: cit0159 doi: 10.1158/1078-0432.CCR-11-2393 – ident: cit0030 doi: 10.1016/j.annonc.2019.10.022 – ident: cit0306 doi: 10.1242/jcs.030197 – ident: cit0058 doi: 10.1016/S1470-2045(17)30680-0 – volume: 17 start-page: A157 issue: 1 year: 2018 ident: cit0151 publication-title: Mol Cancer Ther doi: 10.1186/s12943-018-0906-x – ident: cit0200 doi: 10.2147/OTT.S189391 – ident: cit0098 doi: 10.1016/0167-4781(95)00171-9 – ident: cit0125 doi: 10.1083/jcb.201808077 – ident: cit0173 doi: 10.1038/nature13385 – ident: cit0113 doi: 10.1155/2013/972913 – ident: cit0267 doi: 10.1016/S0025-6196(11)60735-0 – ident: cit0187 doi: 10.1016/S1470-2045(19)30691-6 – ident: cit0055 doi: 10.1177/1060028018824578 – ident: cit0036 doi: 10.1016/j.jtho.2016.11.399 – ident: cit0072 doi: 10.1177/1758834014567470 – ident: cit0257 doi: 10.1016/j.jtho.2019.08.412 – ident: cit0186 doi: 10.1007/978-3-319-91442-8_10 – ident: cit0160 doi: 10.1016/j.cllc.2019.02.013 – ident: cit0294 doi: 10.1038/362841a0 – ident: cit0295 doi: 10.1177/1947601911423031 – volume: 5 start-page: S556 issue: 5 year: 2013 ident: cit0110 publication-title: J Thorac Dis – ident: cit0096 doi: 10.1007/s00432-004-0653-9 – volume: 1 start-page: 33 issue: 2 year: 2018 ident: cit0308 publication-title: Antib Ther – ident: cit0047 doi: 10.1093/oxfordjournals.annonc.a059324 – ident: cit0230 doi: 10.1158/1078-0432.CCR-18-1341 – ident: cit0143 doi: 10.1016/j.cllc.2019.05.003 – ident: cit0261 doi: 10.1080/13543784.2017.1351543 – ident: cit0053 doi: 10.1007/s40271-017-0229-9 – ident: cit0002 doi: 10.21037/tlcr.2016.06.07 – ident: cit0167 doi: 10.1016/j.phrs.2017.04.022 – ident: cit0006 doi: 10.1183/09031936.00126714 – ident: cit0109 doi: 10.1093/annonc/mdw321 – ident: cit0248 doi: 10.1158/1078-0432.CCR-18-1959 – ident: cit0195 doi: 10.2147/OTT.S171665 – volume: 4 start-page: 67 issue: 1 year: 2015 ident: cit0136 publication-title: Transl Lung Cancer Res – ident: cit0118 doi: 10.1007/s10147-012-0386-8 – volume: 1 start-page: 1 issue: 1 year: 2017 ident: cit0142 publication-title: NPJ Precis Oncol doi: 10.1038/s41698-017-0005-2 – ident: cit0005 – volume: 14 start-page: S415 issue: 10 year: 2019 ident: cit0292 publication-title: J Thorac Oncol – ident: cit0056 doi: 10.1016/j.lungcan.2017.06.004 – ident: cit0296 doi: 10.4065/81.9.1241 – ident: cit0026 doi: 10.1158/1541-7786.MCR-19-0419 – ident: cit0184 doi: 10.1007/s12032-017-0967-5 – ident: cit0095 doi: 10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-S – ident: cit0016 doi: 10.1111/j.1349-7006.2012.02327.x |
| SSID | ssj0036701 |
| Score | 2.4255402 |
| SecondaryResourceType | review_article |
| Snippet | Non-small cell lung cancer (NSCLC) comprises of 84% of all lung cancer cases. The treatment options for NSCLC at advanced stages are chemotherapy and... |
| SourceID | proquest pubmed crossref informaworld |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 73 |
| SubjectTerms | immunotherapy Non-small cell lung cancer resistance targeted therapy therapeutics in clinics |
| Title | Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I |
| URI | https://www.tandfonline.com/doi/abs/10.1080/17425247.2021.1825377 https://www.ncbi.nlm.nih.gov/pubmed/32954834 https://www.proquest.com/docview/2444602885 |
| Volume | 18 |
| WOSCitedRecordID | wos000573657100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor & Francis Online Journals customDbUrl: eissn: 1744-7593 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036701 issn: 1742-5247 databaseCode: TFW dateStart: 20041101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYK6qEXCqW0CxRNJcSJwPqR2OGGKlb0gvawVfcW-QlIIYs2u5X239eTx1IOiEM5JpITezxjf2PPfEPIsWXKMhk9VRPNKRFa08Qg6WcEFzT3GWMuqKbYhLy5UdNpPu6iCesurBJ96NASRTRrNRq3NnUfEXceQTRLmZDRu2P0LALklEvMJ49bP9YwmIx-92sxspPRNiUSXS4h-xyel77ybHd6xl36MgJtdqLRxzcYwzbZ6mAoXLZ6s0Pe-eoTORm3PNarU5g8pWXVp3AC4yeG69UuuZs08ePegZsvb6HN4VrBfQXVrErqB12WgDcCUMalBCwq1vwCOgrSEjBmBCOU8D3EEcDjDC2z9LA2hGQcVRp-fia_RleTH9dJV7IhsTzLFgkW_IsYyuV5ag33Q-Gtc8YMvfLCaWFCoJlRWlsjuUglpV6kIc-oN0OLUJLvkc3YU_-VAEsDj76OTL3RSPuuqM9dMC44ZYdShgER_VQVtuMzx7IaZUE72tNexgXKuOhkPCBn62aPLaHHaw3yf_WgWDQnKaEte1LwV9p-75WmiGaLkteVny3rIqIqkUVsp9IB-dJq07o7HO9eFRf7__HnA_IBH5vDInZINhfzpf9G3ts_i_t6fkQ25FQdNabyF0dKDTU |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagIMGFN2V5DhLqqSnrV-xwQ4hVK8pqD0H0ZsUvqJRmq30g7b_Hk8e2PVQ9wDWRE3s8Y39jz3xDyAfHtGMqeao2mVMmqopmFkk_E7igRcgZ81G3xSbUdKpPTorLuTAYVok-dOyIItq1Go0bD6OHkLiPCUUzyYRK7h2jBwkhS67UbXJHpr0Wtbyc_BxWY-Qno11SJDpdQg1ZPNd95sr-dIW99HoM2u5Fk4f_YxSPyIMeicLnTnUek1uheUL2Zh2V9WYfyovMrOU-7MHsguR685T8LtsQ8uDBL9a_oEvj2sBpA828yZZnVV0DXgpAnVYTcKhbi0_Qs5DWgGEjGKSEzyENAc7naJx1gK0tZLOk1XD0jPyYfC2_HGZ91YbM8TxfZVjzL8EoXxTSWR7GIjjvrR0HHYSvhI2R5lZXlbOKC6koDULGIqfBjh2iSf6c7KSehhcEmIw8uTtKBlsh87umofDR-ui1GysVR0QMc2VcT2mOlTVqQ3vm00HGBmVsehmPyMG22XnH6XFTg-KyIphVe5gSu8onht_Q9v2gNSZZLkq-asJ8vTQJWIk8wTstR2S3U6dtdzhev2ouXv7Dn9-Re4fl92NzfDT99orcx1ft2RF7TXZWi3V4Q-66P6vT5eJtazF_AfqGEHg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagINQLb8q2BQYJ9dSU9SOxw60CVlSgVQ6L6M2KX6VSyK42u0j77_HksaWHqge4JnJij2fsb-yZbwh5Z5myTEZP1URzSkRZ0sQg6WcEFzT3GWMuqLbYhJxO1fl5XvTRhE0fVok-dOiIItq1Go174cIQEfc-gmiWMiGjd8foSQTIKZfyLrkXoXOG_tds8mNYjJGejHY5kehzCTkk8dz0mWvb0zXy0pshaLsVTR79h0E8Jg97HAqnneI8IXd8_ZQcFR2R9eYYZld5Wc0xHEFxRXG9eUZ-ztoAcu_ALdcX0CVxbeCyhnpeJ82vsqoArwSgimsJWNSs5QfoOUgrwKARDFHC5xBHAIs5mmblYWsJSRF1Gs6ek--Tz7OPX5K-ZkNieZatEqz4F0GUy_PUGu7HwlvnjBl75YUrhQmBZkaVpTWSi1RS6kUa8ox6M7aIJfkLshN76l8SYGng0dmRqTcl8r4r6nMXjAtO2bGUYUTEMFXa9oTmWFej0rTnPR1krFHGupfxiJxsmy06Ro_bGuR_64FetUcpoat7ovktbd8OSqOj3aLky9rP142OsEpkEdypdET2Om3adofj5aviYv8f_vyGPCg-TfS3s-nXA7KLb9qDI3ZIdlbLtX9F7tvfq8tm-bq1lz-t6A8p |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+drug+therapy+in+non-small+cell+lung+cancer%3A+Clinical+significance+and+possible+solutions-Part+I&rft.jtitle=Expert+opinion+on+drug+delivery&rft.au=Upadhya%2C+Archana&rft.au=Yadav%2C+Khushwant+S.&rft.au=Misra%2C+Ambikanandan&rft.date=2021-01-02&rft.pub=Taylor+%26+Francis&rft.issn=1742-5247&rft.eissn=1744-7593&rft.volume=18&rft.issue=1&rft.spage=73&rft.epage=102&rft_id=info:doi/10.1080%2F17425247.2021.1825377&rft.externalDocID=1825377 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-5247&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-5247&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-5247&client=summon |